Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, MindMaze Therapeutics Holding's Enterprise Value is CHF26.85 Mil.
MindMaze Therapeutics Holding does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate MindMaze Therapeutics Holding's EV-to-EBIT at this moment.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, MindMaze Therapeutics Holding's Enterprise Value is CHF26.85 Mil.
MindMaze Therapeutics Holding does not have enough years/quarters to calculate its EBITDA for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate MindMaze Therapeutics Holding's EV-to-EBITDA at this moment.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, MindMaze Therapeutics Holding's Enterprise Value is CHF26.85 Mil.
MindMaze Therapeutics Holding does not have enough years/quarters to calculate its Revenue for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate MindMaze Therapeutics Holding's EV-to-Revenue at this moment.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
MindMaze Therapeutics Holding (CHIX:MMTXz) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
MindMaze Therapeutics Holding Enterprise Value Related Terms
MindMaze Therapeutics Holding Enterprise Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MindMaze Therapeutics Holding Enterprise Value Chart
MindMaze Therapeutics Holding Annual Data
Trend
Dec24
Dec25
Enterprise Value
0.00
288.08
MindMaze Therapeutics Holding Semi-Annual Data
Dec24
Dec25
Enterprise Value
0.00
288.08
CHIX:MMTXZ vs VRTX, REGN, ALNY: Enterprise Value Comparison
For the Biotechnology subindustry, MindMaze Therapeutics Holding's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MindMaze Therapeutics Holding Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MindMaze Therapeutics Holding's Enterprise Value distribution charts can be found below:
* The bar in red indicates where MindMaze Therapeutics Holding's Enterprise Value falls into.
MindMaze Therapeutics Holding Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of CHF26.85 Mil mean?
MindMaze Therapeutics Holding (CHIX:MMTXZ) has a Enterprise Value of CHF26.85 Mil as of Jul. 02, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on MindMaze Therapeutics Holding and its competitors.
Is MindMaze Therapeutics Holding's Enterprise Value too high?
MindMaze Therapeutics Holding's current Enterprise Value is CHF26.85 Mil. Overall, MindMaze Therapeutics Holding has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does MindMaze Therapeutics Holding's Enterprise Value compare to VRTX and REGN?
MindMaze Therapeutics Holding's Enterprise Value of CHF26.85 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on MindMaze Therapeutics Holding and its competitors. MindMaze Therapeutics Holding's current Enterprise Value is CHF26.85 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindMaze Therapeutics Holding stock overvalued right now?
MindMaze Therapeutics Holding (CHIX:MMTXZ) has a current Enterprise Value of CHF26.85 Mil. The current Enterprise Value is CHF26.85 Mil. MindMaze Therapeutics Holding's overall GF Score™ is 15/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For MindMaze Therapeutics Holding (CHIX:MMTXZ), the current Enterprise Value is CHF26.85 Mil as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MindMaze Therapeutics Holding Business Description
MindMaze Therapeutics Holding SA is a Swiss-based, commercial-stage biopharmaceutical and neurotechnology company. The company develops and commercializes digital treatments for neurological diseases and brain disorders. Its technology platform integrates software, sensors, and telehealth, and its solutions are used in clinical and home settings internationally. The company has developed evidence-based, next-generation neurotherapeutics that provide evidence-based motor and cognitive treatments to redefine clinical outcomes in patients with neurological disease and brain disorders. The company also manages Relief's existing portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases.
15GF Score
Get the complete analysis for CHIX:MMTXZ
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:MMTXZ has been successfully added to your 